• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Ruxolitinib for the Treatment of Refractory Idiopathic Multicentric Castleman Disease: A Case Report.芦可替尼治疗难治性特发性多中心Castleman病：一例报告
Turk J Haematol. 2024 Mar 1;41(1):61-63. doi: 10.4274/tjh.galenos.2024.2023.0477. Epub 2024 Feb 15.
2
Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.特发性多中心 Castleman 病伴 TAFRO 临床亚型对 IL-6/JAK 抑制有反应：儿科病例系列。
Pediatr Blood Cancer. 2021 Oct;68(10):e29261. doi: 10.1002/pbc.29261. Epub 2021 Jul 24.
3
A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease.一项泽布替尼（一种布鲁顿酪氨酸激酶抑制剂）治疗复发/难治性特发性多中心 Castleman 病的前瞻性研究。
Int J Hematol. 2024 Jun;119(6):631-637. doi: 10.1007/s12185-024-03747-7. Epub 2024 Mar 28.
4
Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: A case report.伴有血小板减少、全身水肿、发热、网状纤维纤维化、肾功能不全和器官肿大的难治性特发性多中心 Castleman 病采用 Janus 激酶抑制剂治疗：一例报告。
Medicine (Baltimore). 2022 Dec 2;101(48):e32200. doi: 10.1097/MD.0000000000032200.
5
Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.芦可替尼：一种治疗皮质类固醇难治性急性移植物抗宿主病的潜在药物。
Expert Opin Investig Drugs. 2020 May;29(5):423-427. doi: 10.1080/13543784.2020.1757069. Epub 2020 Apr 19.
6
COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib.鲁索替尼成功治疗一名特发性肺纤维化合并 COVID-19 的患者。
Respir Med Res. 2021 May;79:100799. doi: 10.1016/j.resmer.2020.100799. Epub 2020 Nov 6.
7
Daratumumab for the treatment of refractory idiopathic multicentric Castleman disease: a case report.达雷妥尤单抗治疗难治性特发性多中心Castleman病：一例报告
Ann Hematol. 2022 Nov;101(11):2529-2531. doi: 10.1007/s00277-022-04926-4. Epub 2022 Aug 4.
8
Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid-refractory/dependent acute, gastrointestinal graft-versus-host disease: A case series.以芦可替尼进行粪便微生物群移植作为类固醇难治性/依赖性急性胃肠道移植物抗宿主病的一种治疗方式：病例系列
Am J Hematol. 2021 Dec 1;96(12):E461-E463. doi: 10.1002/ajh.26365. Epub 2021 Oct 9.
9
[Relapsed/refractory idiopathic multicentric Castleman disease successfully treated with sirolimus: a case report].[西罗莫司成功治疗复发/难治性特发性多中心Castleman病：一例报告]
Zhonghua Xue Ye Xue Za Zhi. 2024 May 14;45(5):513. doi: 10.3760/cma.j.cn121090-20240119-00034.
10
Novel Clinical Applications of Topical Ruxolitinib: A Case Series.局部用鲁索替尼的新临床应用：病例系列。
J Drugs Dermatol. 2024 Mar 1;23(3):188-190. doi: 10.36849/jdd.7696.

引用本文的文献

1
Dynamics of Serum Cytokines and Chemokines in Patients With Idiopathic Multicentric Castleman Disease: From a Phase Ib Investigator-Initiated Trial of Filgotinib.特发性多中心Castleman病患者血清细胞因子和趋化因子的动态变化：来自filgotinib的Ib期研究者发起试验
Cureus. 2025 Feb 13;17(2):e78974. doi: 10.7759/cureus.78974. eCollection 2025 Feb.
2
A Phase Ib Investigator-Initiated Trial of Filgotinib in Patients With Idiopathic Multicentric Castleman Disease.一项由研究者发起的filgotinib用于特发性多中心Castleman病患者的Ib期试验。
Cureus. 2025 Feb 11;17(2):e78865. doi: 10.7759/cureus.78865. eCollection 2025 Feb.

本文引用的文献

1
A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD.一项针对新诊断的免疫性血小板减少性紫癜患者使用硼替佐米、环磷酰胺和地塞米松的2期前瞻性研究。 （注：原文中iMCD可能有误，推测为ITP即免疫性血小板减少性紫癜，若不是该病症请根据准确信息修改译文）
Blood. 2023 May 25;141(21):2654-2657. doi: 10.1182/blood.2023020009.
2
Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: A case report.伴有血小板减少、全身水肿、发热、网状纤维纤维化、肾功能不全和器官肿大的难治性特发性多中心 Castleman 病采用 Janus 激酶抑制剂治疗：一例报告。
Medicine (Baltimore). 2022 Dec 2;101(48):e32200. doi: 10.1097/MD.0000000000032200.
3
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.特发性多中心Castleman病中一个新亚组及治疗靶点的发现与验证
Blood Adv. 2021 Sep 14;5(17):3445-3456. doi: 10.1182/bloodadvances.2020004016.
4
JAK1/2 Inhibition in Severe TAFRO Syndrome: A Case Report.JAK1/2 抑制剂治疗重症TAFRO综合征：一例报告
Ann Intern Med. 2021 May;174(5):719-721. doi: 10.7326/L20-1051. Epub 2021 Jan 12.
5
Increased mTOR activation in idiopathic multicentric Castleman disease.特发性多中心 Castleman 病中 mTOR 激活增加。
Blood. 2020 May 7;135(19):1673-1684. doi: 10.1182/blood.2019002792.
6
Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease.采用口服沙利度胺-环磷酰胺-泼尼松治疗特发性多中心 Castleman 病的 2 期研究。
Blood. 2019 Apr 18;133(16):1720-1728. doi: 10.1182/blood-2018-11-884577. Epub 2019 Feb 13.
7
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.特发性多中心 Castleman 病的国际、循证共识治疗指南。
Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4.
8
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.HHV-8阴性/特发性多中心Castleman病的国际循证共识诊断标准。
Blood. 2017 Mar 23;129(12):1646-1657. doi: 10.1182/blood-2016-10-746933. Epub 2017 Jan 13.
9
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.西妥昔单抗治疗多发性 Castleman 病的随机、双盲、安慰剂对照试验。
Lancet Oncol. 2014 Aug;15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. Epub 2014 Jul 17.
10
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.芦可替尼治疗骨髓纤维化的双盲、安慰剂对照试验。
N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557.

Ruxolitinib for the Treatment of Refractory Idiopathic Multicentric Castleman Disease: A Case Report.

作者信息

Gao Yu-Han, Duan Ming-Hui, Li Jian, Zhang Lu

机构信息

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Hematology, Beijing, China

出版信息

Turk J Haematol. 2024 Mar 1;41(1):61-63. doi: 10.4274/tjh.galenos.2024.2023.0477. Epub 2024 Feb 15.

DOI:10.4274/tjh.galenos.2024.2023.0477
PMID:38356196
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10918405/
Abstract
摘要